Leberbezogene Effekte von Exenatid und Dapagliflozin bei Typ-2-Diabetes

Liver-related effects of exenatide and dapagliflozin in type 2 diabetes

This is a preview of subscription content, log in to check access.


  1. 1.

    Jabbour SA, Frías JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C (2018) Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with Metformin Monotherapy: 52-week results of the DURATION‑8 randomized controlled trial. Diabetes Care 41(10):2136–2146

    CAS  Article  Google Scholar 

  2. 2.

    Bedogni G, Bellentani S, Miglioli L et al (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33

    Article  Google Scholar 

  3. 3.

    Kotronen A, Peltonen M, Hakkarainen A et al (2009) Prediction of nonalcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137:865–872

    CAS  Article  Google Scholar 

  4. 4.

    Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854

    CAS  Article  Google Scholar 

  5. 5.

    Nash Clinical Research Network, Shah AG, Lydecker A, Murray K et al (2009) Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7:1104–1112

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Dr. med. Sabine Kahl.

Ethics declarations


S. Kahl gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kahl, S. Leberbezogene Effekte von Exenatid und Dapagliflozin bei Typ-2-Diabetes. Diabetologe 16, 533–534 (2020). https://doi.org/10.1007/s11428-020-00645-4

Download citation